Biliary tract cancer
Treatment in China

Disease Introduction

Biliary duct cancer is a malignant tumor originating from the epithelium of the intrahepatic, hilar, or distal bile ducts. Early stages are often asymptomatic; symptoms such as jaundice, itchy skin, dark urine, and weight loss often indicate an advanced stage. Treatment primarily involves radical surgery. For unresectable or advanced-stage cases, a combination of chemotherapy, immunotherapy, targeted therapy, and jaundice-reducing drainage is used.

Cutting-edge high-precision diagnostic and treatment technologies

1. First-line immunochemotherapy : The TOPAZ-1 regimen of durvalumab combined with gemcitabine and cisplatin resulted in a median overall survival of 12.9 months, which was better than the 11.3 months of chemotherapy alone, and reduced the risk of death by approximately 24%.
2. Keytruda chemotherapy regimen : In the KEYNOTE-966 study, the median overall survival of pembrolizumab combined with gemcitabine and cisplatin was 12.7 months, and it was approved by the US FDA in October 2023.
3. FGFR2 targeting : Pemitinib targets previously treated cholangiocarcinoma with FGFR2 fusion or rearrangement, with an objective response rate of approximately 37% and a median overall survival of 21.1 months;
4. Novel FGFR-targeted therapy : Fabatinib received accelerated approval from the US FDA in September 2022 for previously treated intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement.
5. IDH1 Targeting : Evonib is approved by the US FDA in 2021 for previously treated cholangiocarcinoma with IDH1 mutations.
6. Precision local radiotherapy : The General Hospital of the People's Liberation Army and other hospitals have launched CyberKnife and stereotactic radiotherapy combined with chemotherapy to treat unresectable locally advanced hilar cholangiocarcinoma.